Article Abstract

Checkpoint inhibitors and progressive multifocal leukoencephalopathy: friends of foes?

Authors: Daniele Focosi, Marco Tuccori, Fabrizio Maggi

Abstract

Progressive multifocal leukoencephalopathy (PML) has evolved in the last decade from a disorder of acquired immune deficiency syndrome (AIDS) patients into a rare but fatal complication of several life-saving therapeutics (ranging from rituximab in non-Hodgkin lymphomas to natalizumab in multiple sclerosis). PML is linked to opportunistic reactivation of the latent human JC polyomavirus (JCV), which leads to emergence of neurotropic strains causing brain demyelination.

Article Options

Download Citation